The Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration (FDA) recommended that Eli Lilly and Company’s and Boehringer Ingelheim’s Jardiance (empagliflozin) reduces cardiovascular (CV) death in adults with Type 2 diabetes and established CV disease. Jardiance which is marketed by Boehringer Ingelheim and Eli Lilly, is an oral Type II diabetes medicine shown in a clinical trial to reduce the risk of CV death.

Jardiance, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was approved by the FDA in 2014 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Jardiance is part of the diabetes alliance formed between Eli Lilly and Boehringer Ingelheim in January 2011.

Source: Eli Lilly and Company